SFN and cancer: With increasing amounts of evidence suggesting that Nrf2 is upregulated in cancer cells or resistant strains [52,53], and contributes to the aggressive cancer phenotype [54], it becomes more important to rationalize the usage of Nrf2 activators, such as SFN and its metabolites.